Advertisement

Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study

Published:September 11, 2022DOI:https://doi.org/10.1016/j.jacl.2022.09.002

      Highlights

      • MND-2119 is a self-emulsifying highly purified eicosapentaenoic acid ethyl ester.
      • Long-term administration of MND-2119 was tested in hypertriglyceridemia patients.
      • Triglyceride levels decreased by Week 4 and were maintained up to Week 52.
      • Long-term administration of MND-2119 appeared safe and well tolerated.

      Abstract

      Background

      In Japan, eicosapentaenoic acid ethyl ester (EPA-E) is administered twice-daily or three-times-daily for dyslipidemia. We have developed MND-2119, a novel self-emulsifying formulation of highly purified EPA-E which can be administered once-daily.

      Objective

      The objective of this study was to investigate the safety and efficacy of long-term administration of MND-2119 in hypertriglyceridemia patients.

      Methods

      In this multicenter, 52-week, open-label study, patients with high triglyceride (TG) (TG levels between ≥ 150 and < 500 mg/dL) undergoing lifestyle modification were randomized to MND-2119 2 g/day (n=61) or MND-2119 4 g/day (n=61).

      Results

      The incidence of adverse events in MND-2119 2 g/day and MND-2119 4 g/day was 70.5% and 62.3%, respectively, and the incidence of adverse drug reactions was 9.8% and 8.2%, respectively. There were no notable problems in the safety assessments of both treatment groups. By Week 4, TG levels had decreased from baseline in both groups, and the TG reducing effect continued up to Week 52 (mean percentage change from baseline in TG at Week 52 [two-sided 95% confidence interval]: MND-2119 2 g/day: -16.71% [-26.61, -6.81], MND-2119 4 g/day: -21.01% [-27.86, -14.16]). In both groups, plasma EPA concentration at Week 4 was maintained up until Week 52 and the plasma EPA concentration at Week 52 was 200.5 ± 54.7 μg/mL in MND-2119 2 g/day and 308.6 ± 98.6 μg/mL in MND-2119 4 g/day.

      Conclusion

      Long-term administration of MND-2119 was not associated with any safety-related problems. TG levels decreased by Week 4, and the TG reducing effect continued up to Week 52.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Iso H
        • Imano H
        • Yamagishi K
        • et al.
        Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: The Circulatory Risk in Communities Study (CIRCS).
        Atherosclerosis. 2014; 237 (Nov1): 361-368
        • Hirano T.
        Hypertriglyceridemia: concept and clinical significance.
        Nihon Rinsho. 2013; 71 (Sep): 1519-1527
        • Chris A
        • Peter TKJ
        • Timothy SC
        • et al.
        Revised Adult Treatment Panel III Guidelines and Cardiovascular Disease Mortality in Men Attending a Preventive Medical Clinic.
        Circulation. 2005; 112 (Sep 6): 1478-1485
        • Graham I
        • Atar D
        • Borch-Johnsen K
        • et al.
        European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).
        Eur Heart J. 2007; 28 (Oct): 2375-2414
        • Kinoshita M
        • Yokote K
        • Arai H
        • et al.
        Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.
        J Atheroscler Thromb. 2018; 25 (Sep 1): 846-984
        • Yokoyama M
        • Origasa H
        • Matsuzaki M
        • et al.
        Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
        Lancet. 2007; 369 (Mar 31): 1090-1098
        • Kimura K
        • Kimura T
        • Ishihara M
        • et al.
        JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome.
        Circ J. 2019; 83 (Apr 25): 1085-1196
      1. E1 The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH Website. https://database.ich.org/sites/default/files/E1_Guideline.pdf. Accessed Jan 24, 2022.

        • Bhatt DL
        • Steg PG
        • Miller M
        • et al.
        Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
        N Engl J Med. 2019; 380 (Jan 3): 11-22
        • Tatsuno I
        • Saito Y
        • Kudou K
        • et al.
        Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study.
        J Clin Lipidol. 2013; 7 (Nov-Dec): 615-625
        • Itakura H
        • Yokoyama M
        • Matsuzaki M
        • et al.
        Relationships between Plasma Fatty Acid Composition and Coronary Artery Disease.
        J Atheroscler Thromb. 2011; 18 (Feb 24): 99-107
        • Gorjao R
        • Dos Santos CMM
        • Serdan TDA
        • et al.
        New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids.
        Pharmacol Ther. 2019; 196 (Apr): 117-134
        • Arita M.
        Omega-3 fatty acid metabolism in controlling inflammation and related diseases.
        J Lipid Nutr. 2017; 26 (May 21): 27-34
        • Nagatake T
        • Shiogama Y
        • Inoue A
        • et al.
        The 17, 18-epoxyeicosatetraenoic acid-G protein-coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques.
        J Allergy Clin Immunol. 2018; 142 (Aug 1): 470-484.e12
        • Maki KC
        • Bays HE
        • Ballantyne CM
        • et al.
        A Head-to-Head comparison of a free fatty acid formulation of Omega-3 Pentaenoic acids versus Icosapent ethyl in adults with hypertriglyceridemia: the ENHANCE-IT study.
        J Am Heart Assoc v. 2022; 11 (Mar 15)